Quest Quest Summer/Fall 2017 : Page 3

Advances in Precision Medicine: New “Liquid Biopsy” Blood Test… treatment. For patients who responded well to olaparib, the test showed a nearly 50% reduction in the levels of cancer DNA in the blood after only 8 weeks of treatment. These men lived an average of 17 months after starting the treatment. Comparatively, men who did not respond well to the treatment had an average 2% rise of cancer DNA in their blood, and they lived an average of only 10 months after starting treatment. Third, the test allows physicians to monitor the cancer’s DNA to see if the cancer cells are developing resistance to the drug treatment. In patients who stopped responding to olaparib, the blood test showed that the cancer cells had acquired new genetic changes that cancelled out the original errors in the DNA genes, thus signaling that the treatment would stop working. At this time, the liquid biopsy is being tested in only 49 patients. But, (continued from page 2.) the researchers hope their work could lead to olaparib becoming a new standard of care for patients with advanced prostate cancer who meet the genetic criteria. Cancer Discov. 2017 Apr 27. doi: 10.1158/2159-8290.CD-17-0261. [Epub ahead of print] Contact Information for Dr. Catalona Returning patients : New patients : (312) 695-8146 (312) 695-4471 Upfront Abiraterone: New Research Could Transform Treatment for Men with Advanced Prostate Cancer Results from two studies presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting found that taking that abiraterone upfront with standard hormonal therapy helped men with advanced prostate cancer live longer. If you are unable to schedule a timely appointment, contact Dr. Catalona by phone at 312-695-4471 or mobile text at 314-974-4457. lowered the chance of death by 38% in men newly diagnosed with high-risk, metastatic prostate cancer. Abiraterone also delayed cancer growth by a median of 1.5 years. The study included approximately 1,200 men. T estosterone drives the growth of prostate cancer cells. Androgen deprivation therapy (ADT) stops the testicles from making testosterone and other male hormones, thus slowing the growth of prostate cancer cells. However, the prostate gland and other organs still produce small amounts of testosterone, even if a man is on ADT. The drug abiraterone (Zytiga) is an oral medication that interrupts the androgen-making process at three sources: the testes, the adrenal glands, and in the prostate tumor. Abiraterone is currently approved for use in men with metastatic castration-resistant prostate cancer—cancer that continues to get worse after men are on ADT. The drug is taken in combination with prednisone. Now, new results from two randomized clinical trials suggest that men diagnosed with advanced prostate cancer could benefit from taking abiraterone at the same time they start hormonal therapy, instead of waiting until the disease becomes castration-resistant. Q UEST Summer/Fall 2017 STAMPEDE study The STAMPEDE trial showed that adding abiraterone to standard treatment for high-risk, advanced prostate cancer lowered the relative risk of death by 37%. The 3-year survival rate was 83% for men who added abiraterone to standard therapy, compared to 76% for men on standard therapy alone. Abiraterone also lowered the relative chance of relapse by 70% compared to standard therapy. The study included almost 2,000 men. Standard therapy was defined as being on ADT for at least 2 years. Some patients in the study with locally advanced cancer also received radiation therapy. LATITUDE trial Similar to STAMPEDE, the LATITUDE trial showed that adding abiraterone to hormonal therapy The future of managing advanced cancer Previous study results showed that adding docetaxel (Taxotere), a chemotherapy drug, similarly increased the chances of survival for men with metastatic prostate cancer. Now, the authors of both the STAMPEDE and LATITUDE trials said that future studies are needed to examine whether adding both abiraterone and docetaxel to hormonal therapy could further benefit men diagnosed with advanced prostate cancer. For details on the docetaxel studies, go to www.drcatalona.com and search “docetaxel.” The American Society of Clinical Oncology (ASCO) 2017 Annual Meeting was held June 2-6, 2017 in Chicago. Based on the magnitude of clinical benefit, we believe that the upfront care for patients newly diagnosed with advanced prostate cancer should change. – STAMPEDE study lead author Nicholas James, BSc, MBBS, PhD 3

Upfront Abiraterone: New Research Could Transform Treatment For Men with Advanced Prostate Cancer

Nicholas James

Based on the magnitude of clinical benefit, we believe that the upfront care for patients newly diagnosed with advanced prostate cancer should change.

Results from two studies presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting found that taking that abiraterone upfront with standard hormonal therapy helped men with advanced prostate cancer live longer.

Testosterone drives the growth of prostate cancer cells. Androgen deprivation therapy (ADT) stops the testicles from making testosterone and other male hormones, thus slowing the growth of prostate cancer cells. However, the prostate gland and other organs still produce small amounts of testosterone, even if a man is on ADT.

The drug abiraterone (Zytiga) is an oral medication that interrupts the androgen-making process at three sources: the testes, the adrenal glands, and in the prostate tumor. Abiraterone is currently approved for use in men with metastatic castration-resistant prostate cancer—cancer that continues to get worse after men are on ADT. The drug is taken in combination with prednisone.

Now, new results from two randomized clinical trials suggest that men diagnosed with advanced prostate cancer could benefit from taking abiraterone at the same time they start hormonal therapy, instead of waiting until the disease becomes castrationresistant.

STAMPEDE study

The STAMPEDE trial showed that adding abiraterone to standard treatment for high-risk, advanced prostate cancer lowered the relative risk of death by 37%. The 3-year survival rate was 83% for men who added abiraterone to standard therapy, compared to 76% for men on standard therapy alone.

Abiraterone also lowered the relative chance of relapse by 70% compared to standard therapy.

The study included almost 2,000 men. Standard therapy was defined as being on ADT for at least 2 years. Some patients in the study with locally advanced cancer also received radiation therapy.

LATITUDE trial

Similar to STAMPEDE, the LATITUDE trial showed that adding abiraterone to hormonal therapy lowered the chance of death by 38% in men newly diagnosed with high-risk, metastatic prostate cancer. Abiraterone also delayed cancer growth by a median of 1.5 years.

The study included approximately 1,200 men.

The future of managing advanced cancer

Previous study results showed that adding docetaxel (Taxotere), a chemotherapy drug, similarly increased the chances of survival for men with metastatic prostate cancer. Now, the authors of both the STAMPEDE and LATITUDE trials said that future studies are needed to examine whether adding both abiraterone and docetaxel to hormonal therapy could further benefit men diagnosed with advanced prostate cancer.

For details on the docetaxel studies, go to www.drcatalona.com and search “docetaxel.”

The American Society of Clinical Oncology (ASCO) 2017 Annual Meeting was held June 2-6, 2017 in Chicago.

Read the full article at http://epubs.democratprinting.com/article/Upfront+Abiraterone%3A+New+Research+Could+Transform+Treatment+For+Men+with+Advanced+Prostate+Cancer/2867456/434322/article.html.

Previous Page  Next Page


Publication List
Using a screen reader? Click Here